---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-040811"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:31:34.197989+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Femasys Q3 net loss widens to $2.98M; FemBloc trial enrollment complete, FemaSeed trial updated

## Summary
- Q3 net loss $2.98M ($0.25/share) vs $2.26M ($0.19) YoY; revenue $347K (+28.9% on FemVue).
- FemBloc Stage 2 enrollment complete; IDE for pivotal trial on track for Q1 2023.
- FemaSeed trial updated to focus on male factor infertility; expects enrollment completion in 2023.
- FemCerv commercially launched; FemCath expected by year-end.
- Cash $16.0M at Sept 30, down from $24.8M at Dec 31, 2021.

## SEC filing metadata
- accession: 0001140361-22-040811
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036122040811/0001140361-22-040811-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036122040811/brhc10043970_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-040811
- JSON: https://secwatch.observer/filing/0001140361-22-040811.json
- Plain text: https://secwatch.observer/filing/0001140361-22-040811.txt

## Key facts
- Earnings Releases
  FEMASYS INC reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 10, 2022, Femasys Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2022 and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339005/000114036122040811/0001140361-22-040811-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.